Neverthele ss , the National Institutes of Health (NIH) reports that properl y prescribed sleep medications can be safe and effective . And the new shorter-acting hypnotics rarely produce the next-day lethargy associated with earlier sleep medications .
TYPE OF INSOMNIA DETERMINES TYPE OF TREATMENT
The key to proper use of the hypnotic agents lie s in determining the type of insomnia being experienced. According to an NIH Consensus Panel, there are three basic types: transient insomnia, short-term insomina and long-term insomina (Figure) .
Transient insomnia is related to minor situational stress such as long-distance jet travel or hospitalization for elective surgery. In such cases , physicians often recommend small doses of a short-acting hypnotic , with treatment lasting no more than one to three nights . Other physicians consider drug therapy unnecessary for transient insomnia. Just stick it out, they say; it happens to everyone occasionally. But transient insomnia can be disruptive or even dangerous if it is severe and precedes an important daytime task or a long drive .
Short-t erm insomnia can last up to three weeks and may recur. It is often associated with stress in work or family life, or with illness. In such cases, low doses of a hypnotic agent may be used intermittentl y for up to three weeks , along with avoiding caffeine , alcohol, and daytime naps. The key to effective therapy is intermittent use, since continuous long-term use of hypnotic drugs can, paradoxically, lead to disruption of normal sleep. A short-acting drug is preferable where next-day alertness is desirable. A long-acting drug, on the other hand, may help allay next-day anxiety.
Long-term insomnia is more serious and calls for a complete diagnostic workup. In the absence of serious medical or psychiatric problems , long-term insomnia may respond to a combination of behavioral therapy, better sleep habits and , again , intermittent use of sleep-promoting medications , perhaps one night in three for a limited period of time.
THE MANY FACETS OF SLEEP
The usual amount of sleep obtained and the timing of sleep vary between individuals. The newborn may sleep up to 16 hours per day, distributed in relatively short episodes more or less evenly across the 24hour day. As babies grow older, total sleep time falls and gradually becomes more consolidated at night. Napping may continue for several years. On the other hand, the clearcut sleep-wake periods characteristic of adulthood often break down in the elderly as sleep becomes more shallow and broken, and wakefulness is interrupted by naps or periods of drowsiness.
In addition, people vary in the amount of sleep they require each night. Some people seem to thrive on six hours per night , while others don't feel well rested until they have obtained nine or more Methought I heard a voice cry. "Sleep no more! Macbeth does murder sleep!"
Macbeth and his lady, it would seem , could have used help with a sleep problem. In fact, a lot of us could use help today.
A recent national survey found that one third of the population suffers from some degree of insomnia, and half of that group considers it serious, often leading to high levels of emotional distress .
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hours. No one really knows how much sleep is essential. The amount of sleep any individual needs can be determined by the Multiple Sleep Latency Test used by sleep disorders centers around the country. A practical approach is to ask how alert and rested an individual feels during the day. A chronically sleepy person is either not getting enough sleep or suffers from excessive daytime sleepiness brought on by narcolepsy, sleep apnea, sedating medications, or other medical or psychiatric disorders.
There are many reasons why such problems shouid be investigated, among them the fact that sleep loss accumulates, and the larger the sleep debt becomes, the more likely it is to lead to a potentially dangerous episode of drowsiness.
Because insomnia is so prevalent and significant a problem, the medical community has long sought effective and safe sleep-promoting medications.
Approximately 20 million prescriptions for sleeping pills are written in the United States each year, making them the most widely used of all drugs, according to Mitchel Balter, PhD, former chief of the Applied Therapeutics program of the National Institute of Mental Health. For example, about half of all patients in hospitals receive sleep-promoting medications at some time during their stay.
Nonprescription remedies for sleep are used in even greater volume than prescription drugs, even though their use can present problems. The active ingredient in almost all "nighttime sleep aids" is an antihistamine. Though antihistamines do promote drowsiness, their side effects can include disorientation, confusion, dizziness, ringing in the ears, poor coordination, blurred vision, and irritability.
Alcohol is no help. Certainly a nightcap can lull you to sleep, but it won't be a sound sleep. Thomas Roth, PhD, director of the Sleep Disorders and Research Center at Henry Ford Hospital in Detroit, says alcohol in any pharmacologically active dose disturbs overall sleep.
CHOOSING THE BEST HYPNOTIC
For years, barbiturates were the drugs most commonly used to overcome insomnia. But they can be dangerous, even lethal in high doses. Taken regularly, they lose their effectiveness as tolerance develops. They can cause a cycle of dependence and escalating doses. When combined with alcohol, of course, barbiturates can be deadly.
Chloral hydrate and its derivatives were also prescribed regularly in the past, but 185 70-0701-3396-5 Chapel Hill, NC 27514
Call 800/334-5478 or 800/672-7027 (in NC) for complete information.
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medications, even hypnotic drugs when taken too oftencan also keep you awake. All of these problems must be examined before any individual's insomnia can be properly diagnosed and then properly treated . • The magnitude of the role the artificial heart will playas either a permanent implant or as a bridge to a human heart is still a subject of considerable controversy.
Robert Jarvik, MD, developer of the Jarvik-7 artificial heart and president of Symbion, Inc., in Salt Lake City, Utah, offers his forecast.
"The artificial heart is both an important research tool and a significant clinical advancement," says Jarvik. "There will never be enough human hearts availableto meet the needs of transplant patients. The artificial heart should be developed into a permanently implantable unit. "
While this work stirs controversy, other cardiovascular disease research continues.
CARDIOVASCULAR DISEASE IN THE AGE OF THE ARTIFICIAL HEART
Diseases of the heart and blood vessels remain the leading cause of death in the United States and Europe. However, in the United States since 1964 there has been a significant decline in the overall death rate. Seventy-six percent of the decline can be attributed to a reduction in cardiovascular disease.
"Public education on cardiac risk factors is one element credited for the improved statistics," says Michael DeBakey, MD, chancellor of Baylor College of Medicine in Houston.
In 1985, the American Heart Association (AHA) lowered the minimum blood pressure readings to be diagnosed as high blood pressure from 160 over 95 to 140over 90. The revision significantly increased the 
FOR BENZODIAZEPINES: A WIDE SPECTRUM OF USE
According to the recommendations of a panel of sleep experts convened by the National Institutes of Health, the shorteracting benzodiazepine hypnotics are generally preferred for transient and shortterm insomnia. They are also recommended for such groups as younger patients with liver or kidney problems or geriatric patients, who clear drugs more slowly and are more sensitive to the effects of benzodiazepines. Longer-acting drugs may be preferable, the panel says, as adjunctive therapy in some chronic insomnia or in cases where reduction of next-day anxiety is desirable.
With some other patients, such as those who have sleep apnea or a history of substance abuse, the panel advises caution in the use of any sleep medication.
In all cases, the panel recommends use of the smallest effective dose for the shortest possible time.
Though intermittent use of medication may playa role in treating chronic insomnia, the NIH panel says nonpharmacological approaches such as biofeedback, relaxation techniques, or selfhypnosis may ultimately prove most beneficial. Perhaps even more important may be the identification and treatment of the underlying causes of insomnia. Any illness or physical disorder that induces discomfort or pain can cause insomnia, as can depression, anxiety, schizophrenia, and Alzheimer's disease.
Disorders as varied as cardiac disease, inflammatory bowel disease, and pruritus can all result in a lack of sleep. Then there are the primary sleep disorders: sleep apnea, nocturnal myoclonus, and biological clock disorders. Some medicationsstimulants, thyroid preparations, asthma their effectiveness is soon lost. The risk of overdose is high, and the drugs frequently cause gastric irritation and can lead to internal bleeding. They may also interfere with the effects of other drugs.
The benzodiazepines are currently the drugs of choice to induce sleep. For the most part, they are effective for both shortterm and intermittent use and are nontoxic and nonaddictive. Three of them on the U. S. market today are specifically intended for the treatment of insomnia: flurazepam (Dalmane, Hoffmann-La Roche), temazepam (Restoril, Sandoz) and triazolam (Halcion, Upjohn).
They differ primarily in their rates of absorption and duration of action. Flurazepam is the longest acting, and triazolam is the shortest acting.
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So ELB/Monitor is introducing a new audiovisual program which shows how most accidents can be prevented through personal safety responsibility.
Our new audiovisual program-available in either videotape or slide format-has many applications. You can use it at safety meetings and in new employee orientations. Most ofall, it can mean reduced accidents and associated costs.
The Personal Safety Responsibility Audiovisual program is available from ELB/Monitor for $295.00. 1m! '11_1 __ I Ir"' AT nr\.i""\TU ..11.. Ot"")'l 0 O'lA number of people considered hypertensive. According to AHA, a rationale for the change is that people with blood pressure readings of 140 over 90 and above are at a higher risk of premature death .
ADVANCES IN DIAGNOSIS
The exercise electrocardiogram (EKG), more commonly referred to as the stress test, is a frequently used diagnostic tool.
But its reliability in detecting the presence of coronary artery disease and predicting heart attack risk has been critically questioned in recent years. The stress ' test fared poorly in studies comparing it to cardiac catheterization and angiography. Cardiac catheterization involves insertion of a hollow, flexible tube into a peripheral blood vessel and threading it into the heart. In angiography, contrast dye is injected through the catheter into the heart's blood vessels to give a better x-ray review of coronary blood vessels. Tissue samples may be removed for analysis at the same time.
Echocardiography is a non-invasive diagnostic procedure in which ultrasonic waves are directed toward the heart and reflected (echoed) back for visualization. The procedure depicts the structure and motion of the heart. Exercise followed by echocardiography detects cardiac abnormality with 94 percent accuracy.
Magnetic resonance imaging (MRI) and computerized tomography (CT) are "high tech" non-invasive diagnostic techniques. Although still experimental, they promise to be exciting developments in cardiac medicine. These devices may enable rapid and reliable image analysis of the heart and arteries . MRI utilizes magnetic fields to construct images of the heart . The CT is a technique in which a series of x-rays is used to create detailed three-dimensional pictures of an organ.
NEW DRUGS AFFECTING KIDNEY REGULATION OF BLOOD PRESSURE
Renin, an enzyme produced in the kidney, converts antiotensinogen to angiotensin I. Then angiotensin converting enzyme (ACE) further transforms it to angiotensin II, the most potent vasoconstrictor known. The latter increases arterial blood pressure and stimulates production of aldosterone, a steroid hormone that causes sodium andwater retention. Excess activity in the renin/angiotensin system is suspected in many cases of severe hypertension, especially in patients who do not respond to standard anti-hypertensive Ze ns Tu be-Ba n dage Sy~t e m • Z en s offers yo u a c os t -e f fe c ti ve . s i n g le-so u rce so l u tion for h eel / elbow protectors a n d all yo u r bandaging retain er product s including Tube -Bandage T " . St eri l e fing er·Bandage T " . Starter Ki t, Elastic Dr es sing Retainer a n d Ela st ic Vest Reta in er.
• Z e n s produ ct s a re co m pe ti t i ve l y pric ed a n d a re m anufactured u s ing o n l y th e hi gh est g r ade m at er ial s availabl e . medication. Drugs that inhibit renin synthesis are being developed to treat resistant hypertension. "Renin inhibitors block the key step in angiotensin II synthesis," says Norman Nelson, PhD, associate director of cardiovascular disease research at The Upjohn Company. "We have developed a stable, orally effective renin inhibitor, which is now in early stages of clinical testing."
Already on the market, the ACE inhibitor captopril (Capoten, Squibb) blocks angiotensin II production, leading to a decrease in vasoconstriction and aldosterone release. Because of potentially serious side effects, captopril is reserved for treatment of individuals who do not respond to more moderate therapy, however, in lower doses it may be used for mild hypertension. Newer ACE inhibitors such as enalapril (Vasotec, Merck) with fewer side effects are now available.
PREVENTING SUDDEN CARDIAC DEATH WITH NEW ANTI-ARRHYTHMIC DRUGS
Sudden death due to cardiac arrest may be triggered by an episode of a type of arrhythmia known as ventricular fibrillation -an uncoordinated twitching of the ventricles. Standard anti-arrhythmic drugs reduce the heart's electrical excitability and help to control heart rhythm. However, they also reduce cardiac pumping efficiency -an undesirable side effect in a recuperating heart attack victim.
"We have been studying a new chemical entity that possesses antifibrillatory properties yet has a different mechanism of action than the standard antiarrhythmics," declares John Kenneth Gibson, PhD, research scientist at Upjohn. "In contrast to other anti-arrhythmic agents which depress cardiac contractility, these new agents mildly stimulate cardiac contraction. "
DISSOLVING LIFE-THREATENING BLOOD CLOTS
Tissue-type plasminogen activator (tPA), an enzyme produced by a variety of tissues, dissolves blood clots that block arteries. Tissue plasminogen activator, extracted from human uterine tissue and now also a product of recombinant DNA technology, circulates through the bloodstream until it encounters a blood clot. It then acts specifically on the blood clot to dissolve it.
"Unlike the non-specific thrombolytic agent streptokinase, tPA acts locally and does not produce as much bleeding," says Desire Collen, MD, PhD, professor of medicine at the University of Leuven in 188 Belgium. "In the European trials, recanalization (opening of clogged artery) occurred in about two thirds of the heart attack patients treated with tPA."
In the past two years, clinical testing with tPA has demonstrated that it is twice as effective as streptokinase in opening clogged coronary arteries of heart attack victims. A multicenter clinical study under the direction of the U.S. National Heart, Lung and Blood Institute is under way to further evaluate tPA in the treatment of myocardial infarction.
"We are interested in developing agents that have properties similar to tPA, but which have a longer duration of action, offer greater specificity and can be administered orally," says Ernest W. Yankee, PhD, director, atherosclerosis and thrombosis research at Upjohn.
FISH OIL AND THE PREVENTION OF CORONARY ARTERY DISEASE
Diets rich in certain polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA) may lower serum cholesterol. Greenland Eskimos who eat oily coldwater fish have a lower incidence of cardiovascular disease than people who eat a dairy-and meat-rich diet. Researchers have concluded that increasing the consumption of cold-water fish, such as salmon, mackerel and sardines, which contain large amounts of EPA, may help to reduce the development of atherosclerosis. EPA inhibits the formation of certain prostaglandins that enhance platelet aggregation (clot formation).
REGULATION OF HYPERTENSION WITH DIETARY CALCIUM
Diet plays a pivotal role in blood pressure regulation. The advantages for a significant number of hypertensive patients of restricting dietary sodium and reducing weight are now well established. There may also be an association between reduced calcium intake and elevated blood pressure.
Supplementing daily diets with calcium resulted in a 5% lowering of diastolic pressure in young borderline hypertensive women and a 9% reduction in a similar group of men. Even small changes in blood pressure can yield big health gains in the general population. Long-term studies are needed, however, before researchers can advise the average person to increase dietary calcium.
AN AGING POPULATION: ETHICAL DILEMMAS AND NEW TECHNOLOGIES
Prevention -checking, or at least limit-ing and slowing the development of atherosclerosis -is the most cost-effective way to combat heart disease. Reducing risk factors has proved to be a basic component of preventive medicine over the past 20 years. To date, the greatest costs of prevention have involved large public education campaigns. In contrast, new technologies, developed at tremendous cost -have reached comparatively few critically ill individuals .
On what basis, then, do we decide whether or not to support basic research programs? How do we balance long-and short-term costs and benefits? There are still many unanswered questions that must be addressed. For example, scientists do not know why some people can eat all the cholesterol, saturated at and salt they desire and never develop hypertension or heart disease. Nor do they understand why certain individuals free of known non-genetic risk factors develop heart disease at an early age.
Clearly, heredity plays a role, but how? National statistics do not necessarily have meaning in individual cases, though such cases can help reveal answers to far-reaching problems.
"It is vital that basic research into the causes and treatment of cardiovascular diseases continue," concludes Michael DeBakey, MD, chairman of the department of surgery and chancellor of Baylor College of Medicine in Houston. "In considering the future of cardiovascular medicine, prevention -reducing risk factors -must remain our primary focus."
Likewise, artificial heart research, while having had its share of setbacks, may uncover as yet unknown aspects of human physiology that could have a profound impact on the future of cardiovascular medicine . • 
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